Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 22INDUSTRY 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 31Gliosarcoma 27Astrocytoma 22Brain Neoplasms 17Central Nervous System Neoplasms 16Oligodendroglioma 12Medulloblastoma 9Neuroblastoma 7Glioma 7Choroid Plexus Neoplasms 7Sarcoma 6Melanoma 6Familial ependymoma 6Optic Nerve Glioma 5Spinal Cord Neoplasms 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4Ependymoma 4Uveal Melanoma 3Rhabdomyosarcoma 3Ovarian Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive 3Breast Neoplasms 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pinealoma 2

Interventions

Peripheral Blood Stem Cell Transplantation 5fludarabine phosphate 4Radiotherapy 4Antilymphocyte Serum 4Vincristine 3Vinblastine 3Procarbazine 3Prednisolone 3Methylprednisolone 3Melphalan 3Filgrastim 3Doxorubicin 3Cyclophosphamide 3Chlorambucil 3Busulfan 3Bortezomib 3Bevacizumab 3tipifarnib 2Vorinostat 2Sorafenib 2Oxaliplatin 2Mycophenolic Acid 2Methotrexate 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dacarbazine 2Cyclosporine 2Bleomycin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrence × Temozolomide × Clear all
NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
53 enrolled 22 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡